Etanercept restores a differentiated keratinocyte phenotype in psoriatic human skin: a morphological study.
Tumor Necrosis Factor-α (TNF-α) plays a pivotal role in psoriasis, an immuno-mediated and genetic skin disease. Anti-TNF-α inhibitors, such as etanercept, are widely used in clinical practice. By immunofluorescence, we investigated the expression of junctional transmembrane proteins in desmosomes (desmocollin-1, Dsc1; desmoglein-1, Dsg1), adherens junctions (E-cadherin), tight junctions (occludin), biomarkers of keratinocyte differentiation (keratin-10, K10; keratin-14, K14; keratin-16, K16; involucrin), epithelial proliferation and apoptosis in psoriatic skin before/after etanercept treatment (n = 5) and in control skin samples (n = 5). Occludin, K14, K16 and involucrin expressions were altered in psoriatic epidermis, while Dsc1, Dsg1, E-cadherin and K10 localisations were comparable to controls. Etanercept promoted the restoration of the physiological condition as suggested by a more differentiated keratinocyte phenotype and a reduced epidermal proliferation rate.
Elena
E
Donetti
Alice
A
Gualerzi
Federica
F
Ricceri
Leonardo
L
Pescitelli
Marzia
M
Bedoni
Francesca
F
Prignano
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis; D015820:Cadherins / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D051187:Desmocollins / Q000378:metabolism; D051183:Desmoglein 1 / Q000378:metabolism; D003896:Desmosomes / Q000378:metabolism; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use*; D053550:Keratin-10 / Q000378:metabolism; D053547:Keratin-14 / Q000378:metabolism; D053536:Keratin-16 / Q000378:metabolism; D015603:Keratinocytes / Q000187:drug effects; D062793:Occludin / Q000378:metabolism; D010641:Phenotype; D011498:Protein Precursors / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D019108:Tight Junctions; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015820:Cadherins; C081560:DSC1 protein, human; D051187:Desmocollins; D051183:Desmoglein 1; D007074:Immunoglobulin G; D053547:Keratin-14; D053536:Keratin-16; D062793:Occludin; D011498:Protein Precursors; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D053550:Keratin-10; C032253:involucrin; D000068800:Etanercept